CBD and Rosuvastatin Interaction
Based on current evidence, CBD does not appear to have a clinically significant interaction with rosuvastatin, making concurrent use relatively safe. However, theoretical concerns exist that warrant monitoring.
Key Metabolic Considerations
Rosuvastatin has a unique pharmacokinetic profile among statins that makes it less susceptible to many drug interactions 1:
- Minimal CYP450 metabolism: Rosuvastatin undergoes only minimal metabolism via CYP2C9 (not CYP3A4), with <10% renal excretion 1
- Primary elimination pathway: Relies heavily on hepatic uptake transporters (OATP1B1/1B3) rather than cytochrome P450 enzymes 1
- Low systemic bioavailability: Only 20% absorption with high hepatoselectivity 2
CBD's Interaction Profile
CBD has been shown to interact with several drug-metabolizing enzymes 3, 4:
- CYP2C9 inhibition: CBD inhibits CYP2C9, which is a minor metabolic pathway for rosuvastatin
- CYP3A4 effects: CBD may inhibit CYP3A4, but this is irrelevant for rosuvastatin since rosuvastatin is NOT metabolized by CYP3A4 1
- Transporter effects: Limited evidence suggests CBD may affect drug transporters, though clinical significance remains unclear 4
Why This Combination Appears Safe
The interaction risk between CBD and rosuvastatin is substantially lower than with other statins for these reasons:
Different metabolic pathways: Rosuvastatin's minimal dependence on CYP2C9 (unlike fluvastatin or pitavastatin) reduces the impact of CBD's CYP2C9 inhibition 1
No documented cases: Despite comprehensive reviews of CBD drug interactions, no specific cases of CBD-rosuvastatin interactions causing myopathy or rhabdomyolysis have been reported 5, 3
Clinical trial evidence: A 2024 randomized controlled trial in cancer patients found no increased adverse effects or dose limitations when CBD was used with various concomitant medications 5
Documented High-Risk Rosuvastatin Interactions (For Comparison)
The FDA label and guidelines clearly identify drugs that DO significantly interact with rosuvastatin 6:
- Cyclosporine: 7-fold increase in rosuvastatin exposure - limit to 5 mg daily
- Gemfibrozil: Significantly increased exposure - avoid or limit to 10 mg daily
- Teriflunomide: 2.5-fold increase - limit to 10 mg daily
CBD is not listed among these high-risk interactions in FDA labeling or AHA guidelines 1, 6.
Practical Recommendations
Concurrent use of CBD and rosuvastatin can be considered safe with standard monitoring:
- Monitor for muscle-related symptoms (myalgia, weakness, dark urine) as you would with any statin therapy
- No dose adjustment of rosuvastatin is necessary when initiating CBD
- Check baseline and follow-up creatine kinase if symptoms develop
- Consider liver function tests at baseline and if clinically indicated
Important Caveats
- Dose matters: Most safety data comes from therapeutic CBD doses; extremely high doses may theoretically increase interaction risk
- Individual variation: Patients with genetic polymorphisms in CYP2C9 or OATP transporters may be more susceptible
- Polypharmacy context: If the patient is taking multiple CYP2C9 substrates or OATP inhibitors, cumulative effects should be considered
The combination appears safer than rosuvastatin with gemfibrozil, cyclosporine, or other documented high-risk interactions 1, 6.